Vaccine under development provides the “most comprehensive coverage” to date and alleviates antimicrobial concerns, new study finds
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.
Better access to antibiotics and improved nutrition account for part of the decline. But scientists say it’s mostly due to vaccines introduced in the early 2000s that target up to 23 of the most deadly forms of the bacterium that causes pneumonia, Streptococcus pneumoniae.
Now, a new vaccine under development could deal another blow to the disease, lowering the number of deaths even further by targeting dozens of additional strains of S. pneumoniae, and anticipating future versions of the bacteria responsible for the disease.
The vaccine provoked an immune response to 72 forms of S. pneumoniae — including the 23 mentioned above — in lab tests on animals, according to new research published today (Oct. 20, 2017) in the journal Science Advances. The study represents the “most comprehensive” coverage of pneumococcal disease to date, researchers say.
“We’ve made tremendous progress fighting the spread of pneumonia, especially among children. But if we’re ever going to rid ourselves of the disease, we need to create smarter and more cost-effective vaccines,” says Blaine Pfeifer, PhD, associate professor of chemical and biological engineering at the University at Buffalo’s School of Engineering and Applied Sciences, and the study’s co-lead author.
The limitation of existing vaccines
Each strain of S. pneumoniae contains unique polysaccharides. Vaccines such as Prevnar 13 and Synflorix connect these sugars — by the sharing of an electron — to a protein called CRM197. The process, known as a covalent bond, creates a potent vaccine that prompts the body to find and destroy bacteria before it colonizes the body.
While effective, creating covalent bonds for each strain of S. pneumoniae is time-consuming and expensive. Plus, this type of immunization, known as a conjugate vaccine, prompts the body to eliminate each of the targeted bacteria types — regardless of whether the bacteria is idyll or attacking the body.
Another vaccine, Pneumovax 23, contains sugars of 23 of the most common types S. pneumoniae. However, the immune response it provokes is not as strong as Prevnar because the sugars are not covalently linked.
“Traditional vaccines completely remove bacteria from the body. But we now know that bacteria — and in a larger sense, the microbiome — are beneficial to maintaining good health, says Charles H. Jones, the study’s other co-lead author.
“What’s really exciting is that we now have the ability — with the vaccine we’re developing — to watch over bacteria and attack it only if it breaks away from the colony to cause an illness. That’s important because if we leave the harmless bacteria in place, it prevents other harmful bacteria from filling that space.”
Jones, who earned a PhD while working in Pfeifer’s lab, has formed a company, Abcombi Biosciences, to bring the vaccine and other pharmaceutical products to market. The company is part of the START-UP NY economic development program, was a finalist for the 43North business plan competition in 2016 and has received seed funding and other support from UB.
Co-authors of the study from UB’s engineering school include Guojian Zhang, Roozbeh Nayerhoda, Marie Beitelshees (also of Abcombi), Andrew Hill (also of Abcombi) and Yi Li; Bruce A. Davison and Paul Knight III, both faculty members from the Jacobs School of Medicine and Biomedical Sciences at UB; and Pooya Rostami of New York University’s Langone Medical Center.
How the new vaccine works
Varieties of S. pneumoniae not covered by current immunizations are responsible for a small portion — for example, 7 to 10 percent among U.S. children, according to the Centers for Disease Control and Prevention — of pneumonia, meningitis and other cases of pneumococcal disease.
But officials worry that will change, as these less common forms — and, potentially, yet-to-be discovered antimicrobial resistant strains — replace the 23 more common types targeted by current immunizations.
The new vaccine provokes a strong immune response (comparable to Prevnar) and is engineered in a way that makes it easy to add sugars (like Pneumovax) for a broad immune response.
Key to the technology is a liposome — a tiny liquid-filled bubble made of fat — that acts as a storage tank for the sugars. Because the sugars are not covalently bonded, it’s possible that the liposome could host all of the sugars that identify individual strains of S. pneumoniae.
The research team added proteins at the surface of the liposome (also non-covalently) which, together with the sugars, provoke strong immunotherapy. According to tests performed on mice and rabbits, the new vaccine stimulated an immune response to 72 of the more than 90 known strains of S. pneumoniae. In many cases, it outperformed Prevnar and Pneumovax.
“The advantage of our approach is that we don’t have to apply the more complex covalent chemistry that is required for Prevnar,” Pfeifer says. “As a result, we can extend beyond the 13 types of sugars, potentially providing universal coverage against bacteria that causes pneumonia, meningitis, sepsis and other types of pneumococcal disease.
“It holds the promise of saving hundreds of thousands of lives each year.”
Learn more: The end of pneumonia? New vaccine offers hope.
The Latest on: Pneumonia
- Why This FDA Approval for Pneumonia Treatment Is So Huge on June 19, 2019 at 6:23 am
Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares nearly doubled early on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug ... […]
- Baby wallaby hand-reared in rucksack after mother dies of pneumonia on June 19, 2019 at 3:50 am
An orphaned baby wallaby is being hand-reared in a rucksack after his mother died of pneumonia. The tiny four-month-old, named Riley, is being nurtured by wildlife carer Julia Stewart, who carries him ... […]
- Global Pneumonia Therapeutics Market 2019 Worldwide Industry Analysis by Top Leading Player, Key Regions, Future Demand and Forecast upto 2024 on June 18, 2019 at 10:32 pm
Jun 19, 2019 (Aperture Games via COMTEX) -- Global pneumonia therapeutics market is expected to reach USD 26.37 Billion by 2026, at a CAGR of 8.39% from 2019 to 2026. Growing geriatric population ... […]
- The Subtle, yet Serious, Symptoms of Pneumonia on June 14, 2019 at 1:44 pm
Pneumonia is a common infection that causes the air sacs (alveoli) in the lungs to fill with fluid or pus. The symptoms and severity of pneumonia can vary, depending on the germ that caused ... […]
- Is Tan Mom Dying? New Details On Patricia Krentcil Who Is Currently 'Fighting For Her Life' With Pneumonia on June 12, 2019 at 10:15 am
She first made headlines by bringing her five-year-old daughter to a tanning booth and now she's in the hospital fighting for her life. Is Tan Mom dying? Patricia Krentcil can’t seem to make the news ... […]
- Point of Care eGFR and the Prediction of Outcomes in Pneumonia on June 11, 2019 at 2:14 am
Pneumonia is one of the leading causes of mortality globally 1,2,3. Despite the advancements in medical care, the 30-day mortality of community-acquired pneumonia remains as high as 12.1% in elderly ... […]
- ‘Tan Mom’ is reportedly ‘fighting for her life’ in the hospital during battle with pneumonia on June 10, 2019 at 2:02 pm
Patricia Krentcil, who is known to many as “Tan Mom” after her high-profile 2012 arrest, is reportedly in critical condition battling pneumonia. According to Yahoo, the former Nutley, Essex County, ... […]
- Pneumonia mapped in largest genomic survey of any disease-causing bacterium on June 10, 2019 at 12:53 pm
Researchers have mapped the most common bacterial cause of pneumonia around the world and revealed how these bacteria evolve in response to vaccination. Scientists from the Wellcome Sanger ... […]
- Ventilator-Associated Pneumonia (VAP) Market driven by Awareness towards Hospital Acquired Infection, Global Trends by 2023 on June 10, 2019 at 1:54 am
Jun 10, 2019 (MarketersMedia via COMTEX) -- This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the ... […]
- ‘Tan Mom’ Patricia Krentcil is on life support, battling pneumonia on June 9, 2019 at 11:37 pm
Patricia Krentcil, who became a media sensation known as “Tan Mom” in 2012 after being arrested for taking her 5-year-old to a tanning salon in New Jersey, is reportedly in critical condition due to ... […]
via Google News and Bing News